Unlock instant, AI-driven research and patent intelligence for your innovation.

Antitumor pharmaceutical composition

A composition and anti-tumor technology, applied in the field of pharmaceutical compositions for the treatment of tumors, can solve problems such as limited value and no inhibitory effect

Inactive Publication Date: 2019-03-01
XIAN JIAOTONG LIVERPOOL UNIV
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Disadvantages of the existing protein (i.e. the original TIMP-1): (1) The original TIMP-1 is a soluble secreted protein
(2) TIMP-1 has no inhibitory effect on MT1-MMP and TACE
(3) TIMP-1 can enhance cell activity, which greatly limits its value in cancer research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antitumor pharmaceutical composition
  • Antitumor pharmaceutical composition
  • Antitumor pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] BHK+T1 PrαTACE : Encapsulation and inhibitory effects of the composition on renal cell carcinoma (CaKi-1)

[0053] method:

[0054] 1. Infect Caki-1 cells with the purchased RFP lentivirus (Jiman Biotechnology Co., Ltd.), and then double-screen with blasticidin and flow cytometry to obtain Caki-1 cells with high expression of RFP;

[0055] 2. Cultivate BHK+T1 with complete medium containing 10ug / ml Puromycin PrαTACE Cells, Caki-1 cells were cultured in complete culture medium containing 5ug / ml Blasticidin, and a sufficient number of cells were obtained for use;

[0056] 3. Count the two types of cells with an automatic cell counter;

[0057] 4. Resuspend 50,000 BHK+T1 in 40ul liquid Matrigel PrαTACE cells, and then add the same volume of culture medium containing 50,000 Caki-1 cells, mix thoroughly, and finally take 8ul of the mixture and drop it into a 24-well culture plate;

[0058] 5. Place it at 37°C until the Matrigel solidifies, then add complete cultur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention belongs to the technical field of biological medicine, and relates to an antitumor pharmaceutical composition comprising BHK-21 cells expressing T1<Pr alpha TACE> protein and anartificial basement membrane. Preferably, the pharmaceutical composition comprises BHK-21 fibroblasts expressing T1<Pr alpha TACE> protein at a final concentration of 300000 to 625000 per mL, 30% to 60% by weight of an artificial basement membrane, and 5% of Dulbecco's culture solution of fetal bovine serum.

Description

technical field [0001] The invention relates to the technical field of biomedicine, and specifically relates to a pharmaceutical composition for treating tumors. Background technique [0002] Current cancer treatment technologies can be roughly divided into three categories: [0003] 1. Chemotherapy: The most common side effects of chemotherapy include nausea and vomiting, hair loss, immunosuppression, and loss of appetite. [0004] 2. Radiation therapy: The side effects of radiation therapy are usually milder than those of chemotherapy. Skin reactions such as desquamation, erythema, and fibrosis are radiation-related side effects. In addition, this treatment method also requires specialized treatment equipment and environments such as hospitals. [0005] 3. Immunotherapy: Immune-related symptoms such as fatigue, fever, weakness, nausea, body aches, and high blood pressure are common side effects of immunotherapy. [0006] Therefore, there are many defects and drawbacks ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/22A61K38/57A61K47/46A61P35/00A61P35/02
CPCA61K38/57A61K47/46A61P35/00A61P35/02A61K35/22
Inventor 李明辉刘坚姜冰洁
Owner XIAN JIAOTONG LIVERPOOL UNIV